IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Clinical trial NCT05155254 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05155254
- Sponsor
- IO Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-17
- Primary completion
- 2025-05-30
- Enrollment
- 407
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.